Idelalisib for Treating Chronic Lymphocytic Leukaemia (TA359)

Technology Appraisal Guidance No. 359

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Idelalisib, in combination with rituximab, is recommended:

  • for untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation or
  • for chronic lymphocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months
  • if the company provides the drug with the discount agreed in the simple discount agreement.
1.2 People whose treatment with idelalisib is not recommended in this NICE guidance but was started within the NHS before this guidance was published should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

 


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA359

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Idelalisib for treating chronic lymphocytic leukaemia

Issue Date: October 2015

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more